MedPath

Probiotics on Immune Function and Intestinal Microbiota in Astronauts Under Closed Microgravity Environment

Not Applicable
Conditions
Immune Function and Intestinal Microbiota
Registration Number
NCT02618005
Lead Sponsor
Yakult Honsha Co., LTD
Brief Summary

Human immune function and intestinal microbiota are suggested to be altered within long-duration stay in space. Accumulated evidences on earth support that Lactobacillus casei strain Shirota (LcS) is a promising probiotic strain on improvement of immune function and intestinal microbiota. This study aims to investigate the impact of long-duration spaceflight as well as intake of LcS on the international space station (ISS), on immune system and intestinal microbiota in astronauts.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
10
Inclusion Criteria
  • Individuals who are scheduled to stay on the ISS for at least 3 months
  • Individuals who fully understand the study protocol and provide written informed consent for the study participation
Exclusion Criteria
  • Individuals who routinely use antibiotic, laxative, and/or bowel regulating medicine
  • Individuals who participate in other research that competes with this study in terms of the purpose and field, e.g., study with dietary management or intake of bifidobacteria/lactic acid bacteria, oligosaccharides, antibiotic, laxative, and/or bowel regulating medicine

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Longitudinal changes in the number of LcS in feces9-18 months

Number of LcS in feces will be assessed by PMA-qPCR, during pre-flight, in-flight and post-flight.

Longitudinal changes in the level of immune markers9-18 months

Levels of immune markers in blood/saliva will be assessed by ELISA and bioassay, during pre-flight, in-flight and post-flight.

Longitudinal changes in numbers and composition of intestinal microbiota9-18 months

Numbers and composition of bacteria in feces will be assessed by RT-qPCR/qPCR and next generation sequencer analysis, during pre-flight, in-flight and post-flight.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Japan Aerospace Exploration Agency

🇯🇵

Ibaraki, Japan

Japan Aerospace Exploration Agency
🇯🇵Ibaraki, Japan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.